Serum N-terminal pro-B-type natriuretic peptide levels are associated with functional capacity in patients with peripheral arterial disease

Angiology

Volumn 63, Issue 6, 2012, Pages 435-442

  Fan, Jin ^a   Jouni, Hayan ^a   Khaleghi, Mahyar ^b   Bailey, Kent R ^a   Kullo, Iftikhar J ^a  

^a MAYO CLINIC   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

functional capacity; N terminal pro B type natriuretic peptide; natriuretic peptides; peripheral arterial disease

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGE; AGED; ANKLE BRACHIAL INDEX; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; COMORBIDITY; CONTROLLED STUDY; CORRELATIONAL STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG USE; DYSLIPIDEMIA; FEMALE; FUNCTIONAL STATUS; GENDER; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL PARAMETERS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROTEIN BLOOD LEVEL; PULSE PRESSURE; QUANTITATIVE ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREADMILL; TRIACYLGLYCEROL BLOOD LEVEL; WALKING DISTANCE;

AGED; BIOLOGICAL MARKERS; EXERCISE TEST; EXERCISE TOLERANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEG; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PERIPHERAL ARTERIAL DISEASE; PROGNOSIS; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; WALKING;

EID: 84862732016     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319711423095     Document Type: Article

References (43)

1. Belch JJ, Topol EJ, Agnelli G, et al. Critical issues in peripheral arterial disease detection and management: a call to action. Arch Intern Med. 2003;163(8):884-892. (Pubitemid 36519734)
2. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review. Circulation. 1996;94(11):3026-3049. (Pubitemid 26411793)
3. Criqui MH, Denenberg JO, Langer RD, Fronek A. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2(3):221-226. (Pubitemid 27468155)
4. Murabito JM, D'Agostino RB, Silbershatz H, Wilson WF. Intermittent claudication. A risk profile from the framingham heart study. Circulation. 1997;96(1):44-49. (Pubitemid 27298402)
5. Gornik HL, Creager MA. Contemporary management of peripheral arterial disease: I. cardiovascular risk-factor modification. Cleve Clin J Med. 2006;73(suppl 4):S30-S37.
6. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA. 2001;286(13):1599-1606. (Pubitemid 33010284)
7. Newman AB, Naydeck BL, Sutton-Tyrrell K, Polak JF, Kuller LH. The role of comorbidity in the assessment of intermittent claudication in older adults. J Clin Epidemiol. 2001;54(3):294-300. (Pubitemid 32153872)
8. Amoh-Tonto CA, Malik AR, Kondragunta V, Ali Z, Kullo IJ. Brachial-ankle pulse wave velocity is associated with walking distance in patients referred for peripheral arterial disease evaluation. Atherosclerosis. 2009;206(1):173-178.
9. Brewer LC, Chai HS, Bailey KR, Kullo IJ. Measures of arterial stiffness and wave reflection are associated with walking distance in patients with peripheral arterial disease. Atherosclerosis. 2007;191(2):384-390. (Pubitemid 46400700)
10. Tokudome T, Kishimoto I, Yamahara K, et al. Impaired recovery of blood flow after hind-limb ischemia in mice lacking guanylyl cyclase-a, a receptor for atrial and brain natriuretic peptides. Arterioscler Thromb Vasc Biol. 2009;29(10):1516-1521.
11. Jouni H, Rodeheffer RJ, Kullo IJ. Increased serum N-terminal pro-B-type natriuretic peptide levels in patients with medial arterial calcification and poorly compressible leg arteries. Arterioscler Thromb Vasc Biol. 2011;31(1):197-202.
12. Montagnana M, Lippi G, Fava C, et al. Ischemia-modified albumin and NT-prohormone-brain natriuretic peptide in peripheral arterial disease. Clin Chem Lab Med. 2006;44(2):207-212. (Pubitemid 43237967)
13. Svensson P, de Faire U, Niklasson U, Hansson LO, Ostergren J. Plasma NT-pro-BNP concentration is related to ambulatory pulse pressure in peripheral arterial disease. Blood Press. 2005;14(2):99-106. (Pubitemid 40645497)
14. Dieplinger B, Poelz W, Haltmayer M, Mueller T. Association of adiponectin and amino terminal proBNP in peripheral arterial disease. Clin Chim Acta. 2007;377(1-2):192-197. (Pubitemid 44908250)
15. Mueller T, Dieplinger B, Poelz W, Endler G, Wagner OF, Haltmayer M. Amino-terminal pro-B-type natriuretic peptide as predictor of mortality in patients with symptomatic peripheral arterial disease: 5-year follow-up data from the linz peripheral arterial disease study. Clin Chem. 2009;55(1):68-77.
16. Santos S, Rooke TW, Bailey KR, McConnell JP, Kullo IJ. Relation of markers of inflammation (C-reactive protein, white blood cell count, and lipoprotein-associated phospholipase a2) to the ankle-brachial index. Vasc Med. 2004;9(3):171-176. (Pubitemid 40124080)
17. Gardner AW, Skinner JS, Cantwell BW, Smith LK. Progressive vs single-stage treadmill tests for evaluation of claudication. Med Sci Sports Exerc. 1991;23(4):402-408.
18. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the american association for vascular surgery/society for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease) endorsed by the american association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; transatlantic inter-society consensus; and vascular disease foundation. J Am Coll Cardiol. 2006;47(6):1239-1312.
19. Levey AS, Coresh J, Greene T, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247-254. (Pubitemid 46768608)
20. McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg function and physical activity: the walking and leg circulation study. Ann Intern Med. 2002;136(12):873-883. (Pubitemid 34625699)
21. Luchner A, Burnett JC Jr, Jougasaki M, Hense HW, Riegger GA, Schunkert H. Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol. 1998;32(7):1839-1844. (Pubitemid 29010443)
22. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347(3):161-167. (Pubitemid 34764819)
23. Cheng EM, Asch SM, Brook RH, et al. Suboptimal control of atherosclerotic disease risk factors after cardiac and cerebrovascular procedures. Stroke. 2007;38(3):929-934. (Pubitemid 46568455)
24. Dao HH, Essalihi R, Bouvet C, Moreau P. Evolution and modulation of age-related medial elastocalcinosis: impact on large artery stiffness and isolated systolic hypertension. Cardiovasc Res. 2005;66(2):307-317. (Pubitemid 40471045)
25. Ferreira I, Twisk JW, Van Mechelen W, Kemper HC, Stehouwer CD. Current and adolescent levels of cardiopulmonary fitness are related to large artery properties at age 36: the amsterdam growth and health longitudinal study. Eur J Clin Invest. 2002;32(10):723-731. (Pubitemid 35334966)
26. O'Rourke MF. Mechanical principles. Arterial stiffness and wave reflection. Pathol Biol (Paris). 1999;47(6):623-633.
27. Her K, Choi C, Park Y, Shin H, Won Y. Concomitant peripheral artery disease and asymptomatic coronary artery disease: a management strategy. Ann Vasc Surg. 2008;22(5):649-656.
28. McDermott MM, Liu K, Criqui MH, et al. Ankle-brachial index and subclinical cardiac and carotid disease: the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2005;162(1):33-41. (Pubitemid 40884998)
29. Lester SJ, Tajik AJ, Nishimura RA, Oh JK, Khandheria BK, Seward JB. Unlocking the mysteries of diastolic function: deciphering the rosetta stone 10 years later. J Am Coll Cardiol. 2008;51(7):679-689. (Pubitemid 351221211)
30. Rubattu S, Sciarretta S, Valenti V, Stanzione R, Volpe M. Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens. 2008;21(7):733-741. (Pubitemid 351913612)
31. Kuhn M, Volker K, Schwarz K, et al. The natriuretic peptide/ guanylyl cyclase - a system functions as a stress-responsive regulator of angiogenesis in mice. J Clin Invest. 2009;119(7): 2019-2030.
32. Chen H, Levine YC, Golan DE, Michel T, Lin AJ. Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem. 2008;283(7):4439-4447.
33. Park K, Itoh H, Yamahara K, et al. Therapeutic potential of atrial natriuretic peptide administration on peripheral arterial diseases. Endocrinology. 2008;149(2):483-491. (Pubitemid 351159359)
34. Shmilovich H, Ben-Shoshan J, Tal R, et al. B-type natriuretic peptide enhances vasculogenesis by promoting number and functional properties of early endothelial progenitor cells. Tissue Eng Part A. 2009;15(9):2741-2749.
35. Charles CJ, Espiner EA, Richards AM. Cardiovascular actions of ANF: contributions of renal, neurohumoral, and hemodynamic factors in sheep. Am J Physiol. 1993;264(3 pt 2):R533-R538. (Pubitemid 23109901)
36. Yamahara K, Itoh H, Chun TH, et al. Significance and therapeutic potential of the natriuretic peptides/cGMP/cGMP-dependent protein kinase pathway in vascular regeneration. Proc Natl Acad Sci U S A. 2003;100(6):3404-3409. (Pubitemid 36356596)
37. Mukherjee S,MukhopadhyayP,PanditK,Chowdhury S. Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes. J Indian Med Assoc. 2008;106(11):716-719.
38. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG coA reductase inhibitors. Circulation. 1998;97(12):1129-1135. (Pubitemid 28152885)
39. Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92(6):711-712. (Pubitemid 37103026)
40. Momsen AH, Jensen MB, Norager CB, Madsen MR, Vestersgaard- Andersen T, Lindholt JS. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009;38(4):463-474.
41. Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension. 2005;45(6):1194-1199. (Pubitemid 40770326)
42. Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. J Hypertens. 2008; 26(5):1037-1042.
43. Anand RG, Ventura HO, Mehra MR. Is heart failure more prevalent in patients with peripheral arterial disease? A meta-analysis. Congest Heart Fail. 2007;13(6):319-322.